PRLD – prelude therapeutics incorporated (US:NASDAQ)
Stock Stats
News
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies [Yahoo! Finance]
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Form 4 Prelude Therapeutics For: Dec 19 Filed by: Lim Bryant David
Form 4 Prelude Therapeutics For: Dec 18 Filed by: Vaddi Krishna
Form 8-K Prelude Therapeutics For: Dec 11
Form 10-Q Prelude Therapeutics For: Sep 30
Form 8-K Prelude Therapeutics For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.